Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor | PNAS
Meet the Compound: Laquinimod – HD Insights
Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study - The Lancet
Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis | NEJM
Heart Incidents End Parts of Two Studies by Teva, Active Biotech - WSJ
Teva, Active Biotech Present Positive Findings for RRMS Experimental Therapy Laquinimod
Linomide - Wikipedia
Laquinimod sodium (ABR-215062 sodium) | Immunomodulator | MedChemExpress
Teva & Active Biotech Press Release: November 4, 2014
After Multiple Failures, Teva Returns Laquinimod Rights to Active Biotech | BioSpace
With EU knockback laquinimod's irrelevance is all but assured | Evaluate
laquinimod
Active Biotech Regains Rights to Laquinimod from Teva, Plans to Continue Work on Potential MS Oral Therapy
Teva Relinquishes Laquinimod, Returning the Rights to Active Biotech - Pharmaceutical Processing World
Laquinimod Therapy in Multiple Sclerosis: A Comprehensive Review | SpringerLink
Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System Autoimmunity | PLOS ONE
Laquinimod prevents cuprizone-induced demyelination independent of Toll-like receptor signaling
Teva backs laquinimod for MS despite CHMP rejection - PMLiVE
Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells - Dobson - 2016 - Journal of Neurochemistry - Wiley Online Library
Laquinimod | C19H17ClN2O3 - PubChem
CONFIDENTIAL DRAFT: Failure Scenario (PEP Not Achieved)
Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download
First patient enrolled in Phase II study evaluating laquinimod
Teva finally dumps laquinimod, ending failure-riddled saga | Fierce Biotech
The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women | Request PDF
Teva, Active Biotech Partner To Develop Laquinimod For Huntington's Disease
